Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
What price target have analysts set for ZLAB?
3 equities research analysts have issued twelve-month target prices for Zai Lab's stock. Their forecasts range from $34.70 to $43.00. On average, they anticipate Zai Lab's share price to reach $38.85 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
Press coverage about ZLAB stock has trended very positive recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zai Lab earned a news sentiment score of 3.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next few days.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Perrigo (PRGO), Marina Biotech (MRNA), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR), Array Biopharma (ARRY), Ascendis Pharma A/S (ASND), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Horizon Pharma (HZNP) and Amneal Pharmaceuticals (AMRX).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Segantii Capital Management Ltd (4.13%), BlackRock Inc. (0.74%), Tree Line Advisors Hong Kong Ltd. (0.72%), Millennium Management LLC (0.46%), Hudson Bay Capital Management LP (0.40%) and WealthPLAN Partners LLC (0.30%).
Which institutional investors are selling Zai Lab stock?
ZLAB stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Millennium Management LLC and Squarepoint Ops LLC.
Which institutional investors are buying Zai Lab stock?
ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Tree Line Advisors Hong Kong Ltd., BlackRock Inc., WealthPLAN Partners LLC, Polar Capital LLP, Diag Capital Management LP, Hudson Bay Capital Management LP, RBF Capital LLC and Matthews International Capital Management LLC.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $30.04.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $1.75 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
